Skip to content

Richard Baird

  • MD, PhD
  • Academic Consultant in Experimental Cancer Therapeutics
  • University of Cambridge
  • 15h-indexImpact measure calculated using publication and citation counts. Updated daily.
  • 1271CitationsNumber of citations received by Richard's publications. Updated daily.

Research interests

Breast cancer therapeuticsBiomarker developmentNew drug development


• Cancer researcher and medical oncologist at Cambridge University Hospitals, U.K. • Trained at University of Cambridge and Institute of Cancer Research / Royal Marsden Hospital. • Specialist in the care of breast cancer patients. • MD with PhD in molecular pharmacology and cancer drug development. • Expert in the testing of novel therapeutic approaches for breast cancer patients, including: o Design and delivery of early phase clinical trials as principal / chief investigator. o Looking after patients taking part in these trials. o Particular research focus on development of: novel targeted therapies; drug combinations; better approaches for patients with brain metastases; companion biomarkers to identify patients most likely to respond to treatment – including liquid biopsies / circulating tumor DNA o Collaboration with industry partners to plan the best clinical development strategy. • Since 2002 co- or Principal Investigator on >80 phase 1 / 2 clinical trials. • Currently Chief or co-Chief Investigator on 3 multi-centre investigator-initiated clinical trials. • Member of trial management group for national and international trials. • UK national academic lead for the Association of Cancer Physicians.

Co-authors (290)

Publications (5)

  • G1T38, An Oral CDK4/6 Inhibitor, Dosed Continuously in Combination with Fulvestrant for HR+ Breast Cancer: Preliminary Phase 1b Results Antitumor Activity and Duration of Treatment

    • Bulat I
    • Maglakelidze M
    • Murias C
    • et al.
  • Copy-number scores from shallow whole-genome sequencing are versatile quantitative markers in liquid biopsy

    • Chandrananda D
    • Mouliere F
    • Ahlborn L
    • et al.
  • OT1-03-02 - MP0274-CP101: A phase 1, first-in-human, single-arm, multi-center, open-label, dose escalation study to assess safety , tolerability , and pharmacokinetics of MP0274 in patients with advanced HER2-positive solid tumors

    • Baird R
    • Omlin A
    • Kiemle-Kallee J
    • et al.
  • OT1-06-03. The plasmaMATCH trial: A multiple parallel cohort, open-label, multi-centre phase II clinical trial of ctDNA screening to direct targeted therapies in patients with advanced breast cancer (CRUK/15/010)

    • Turner N
  • Perspectives in Gynecologic Oncology

    • Baird R
    • Van Hagen T
    Get full text

Professional experience

Academic Consultant in Experimental Cancer Therapeutics

University of Cambridge

June 2011 - Present

Senior Clinical Research Fellow, Drug Development Unit

Royal Marsden Hospital & Institute of Cancer Research

September 2009 - June 2011(2 years)

Specialist Registrar in Medical Oncology

Royal Marsden Hospital

September 2005 - August 2009(4 years)

Clinical Research Fellow

Institute of Cancer Research

February 2002 - August 2005(4 years)

Training in general (internal) medicine

Hospitals in London and SE England

August 1997 - February 2002(5 years)


MRCP, General (Internal) Medicine

Royal College of Physicians

April 2001

MBBS, Medicine

King's College Medical School

September 1994 - June 1997(3 years)

MA, Social and Political Science

University of Cambridge

October 1991 - June 1994(3 years)